20/20 BioLabs reports Q1 2026 revenue of $0.4M; expects growth from state firefighter programs

20/20 BioLabs reported Q1 2026 revenue of $0.4 million and raised $5.0 million in private placement, with cash position of $4.2 million as of March 31, 2026. The company expects meaningful revenue growth in Q2 2026 from Maryland's state-funded firefighter cancer screening program and recently secured additional strategic partnerships including ROKIT Healthcare CKD license and Evexia Diagnostics distribution agreement.